Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $89 | $189 | $35 | $15 |
| Short-Term Investments | $514 | $150 | $21 | $78 |
| Receivables | $0 | $0 | $0 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $2 | $6 | $5 |
| Total Curr. Assets | $608 | $342 | $62 | $99 |
| Property Plant & Equip (Net) | $0 | $0 | $7 | $8 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $2 | $3 |
| Total NC Assets | $0 | $0 | $9 | $11 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $608 | $342 | $71 | $110 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $3 |
| Short-Term Debt | $0 | $0 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $1 | $2 |
| Other Curr. Liab. | $53 | $31 | $13 | $14 |
| Total Curr. Liab. | $54 | $32 | $15 | $20 |
| LT Debt | $0 | $0 | $4 | $5 |
| Deferred Rev, NC | $0 | $0 | $2 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $37 | $126 | $0 | $0 |
| Total NC Liab. | $37 | $126 | $6 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $5 | $5 |
| Total Liabilities | $91 | $158 | $21 | $26 |
| Equity | – | – | – | – |
| Pref Stock | $156 | $185 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$972 | -$764 | -$426 | -$342 |
| AOCI | $0 | $0 | -$0 | -$0 |
| Other Equity | $1,334 | $763 | $476 | $426 |
| Total Equity | $518 | $184 | $50 | $84 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $608 | $342 | $71 | $110 |
| Net Debt | -$89 | -$189 | -$30 | -$10 |